AMRN — Amarin Corporation plc

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$309.8M

P/E Ratio

-160.62

Beta

0.82

52-Week Range

8.94-20.9

Dividend Yield

$0.00

CEO

Aaron D. Berg

Employees

275

IPO Date

Apr 1, 1993

Exchange

NASDAQ